Abstract PD13-08: First-in-human safety and activity of ARV-471, a novel PROTAC® estrogen receptor degrader, in ER+/HER2- locally advanced or metastatic breast cancer

富维斯特朗 医学 药效学 转移性乳腺癌 不利影响 乳腺癌 内科学 雌激素受体 肿瘤科 癌症 药理学 药代动力学
作者
Erika Hamilton,Linda T. Vahdat,Hyo S. Han,J. Ranciato,Richard Gedrich,Chi Fung Keung,Deborah Chirnomas,Sara A. Hurvitz
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:82 (4_Supplement): PD13-08 被引量:28
标识
DOI:10.1158/1538-7445.sabcs21-pd13-08
摘要

Abstract Background: Resistance to current endocrine therapies remains a clinical challenge. Fulvestrant has established estrogen receptor (ER) degradation as a critical therapeutic strategy characterized by approximately 50% ER degradation, a clinical benefit rate (CBR) of < 20% in the post CDK 4/6 setting, and a suboptimal intramuscular route of administration. ARV-471 is a selective, orally bioavailable PROteolysis-TArgeting Chimera (PROTAC®) small molecule that induces degradation of wildtype and mutant ER. ARV-471 demonstrates superior ER degradation and antitumor activity compared to fulvestrant in endocrine sensitive and resistant xenograft models. Methods: This is a multi-center, first-in-human, open label study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of ARV-471 administered orally in patients with ER+/HER2- advanced/metastatic breast cancer. The phase 1 monotherapy dose escalation used a 3+3 design with backfill to assess ARV-471 in pre-/post-menopausal women. Premenopausal women had to be on ovarian suppression. Patients were required to have received at least one prior CDK 4/6 inhibitor and at least 2 prior endocrine therapies. Up to 3 prior lines of chemotherapy were allowed. Results: As of June 6th, 2021, 50 patients were treated in the monotherapy escalation at total daily doses of 30mg (n=3), 60mg (n=3), 120mg (n=7), 180/200mg (n=11), 360mg (n=15), 500mg (n=8), and maximum administered dose of 700mg (n=3). A maximum tolerated dose was not reached and no dose limiting toxicities (DLTs) were observed. The most common (≥ 10%) treatment related adverse events (TRAEs) were nausea (24%), fatigue (12%), and vomiting (10%) that were predominantly grade 1 in severity. Two patients experienced grade 3 adverse events (AEs) that were potentially related to ARV-471: 1 patient treated at 180mg had a transient headache lasting 1 day, and 1 patient treated at 360mg had a venous thromboembolism (VTE) a few days after a minor procedure. There were no AEs > grade 3 potentially related to ARV-471. All AEs were manageable with only one patient discontinuing ARV-471 due to a TRAE (grade 3 VTE). ARV-471 demonstrated a dose-related increase in plasma exposure up to 500mg, with doses of 60mg daily and above resulting in steady-state Cmax and AUC24 that exceeded the exposure associated with tumor regression in preclinical models. Analysis of 12 paired biopsies from patients treated at 30 to 360mg daily demonstrated up to 90% ER degradation in tumors expressing WT or mutant ER. Of 34 patients who were evaluable for clinical benefit (confirmed complete response, partial response, or stable disease ≥ 24 weeks) the CBR was 41%. As of the data cutoff date, 6 of the 34 patients were continuing to receive study treatment, including 2 patients who had been on treatment for over 16 months. Two confirmed partial responses were observed among the 28 patients with baseline measurable disease and at least 1 on-treatment tumor assessment. Conclusion: ARV-471 was well tolerated with no DLTs at total daily doses up to 700mg. ARV-471 demonstrated robust ER degradation in paired biopsy samples and encouraging clinical activity (41% CBR) in patients who received prior CDK 4/6 inhibitors. ARV-471 is now being evaluated in the VERITAC Phase 2 monotherapy expansion at 200 mg and 500 mg once daily. Citation Format: Erika Hamilton, Linda Vahdat, Hyo S Han, Jennifer Ranciato, Richard Gedrich, Chi F Keung, Deborah Chirnomas, Sara Hurvitz. First-in-human safety and activity of ARV-471, a novel PROTAC® estrogen receptor degrader, in ER+/HER2- locally advanced or metastatic breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr PD13-08.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
怕孤单的听寒完成签到,获得积分10
3秒前
5秒前
6秒前
zeng123完成签到,获得积分20
9秒前
10秒前
吉吉国王完成签到 ,获得积分10
11秒前
谨慎的豆芽完成签到 ,获得积分10
11秒前
13秒前
13秒前
科研通AI2S应助科研通管家采纳,获得10
14秒前
Frank应助科研通管家采纳,获得100
14秒前
丘比特应助科研通管家采纳,获得10
14秒前
上官若男应助科研通管家采纳,获得10
15秒前
田様应助科研通管家采纳,获得10
15秒前
加菲丰丰应助科研通管家采纳,获得10
15秒前
科研通AI2S应助科研通管家采纳,获得10
15秒前
无花果应助科研通管家采纳,获得10
15秒前
19秒前
丘比特应助mmlb采纳,获得10
20秒前
老衲法号嘿嘿嘿完成签到,获得积分10
22秒前
24秒前
ataybabdallah完成签到,获得积分20
25秒前
cai完成签到,获得积分10
25秒前
壮观小鸭子完成签到 ,获得积分10
26秒前
1huiqina发布了新的文献求助30
27秒前
星辰大海应助fangplus采纳,获得10
30秒前
一只想做科研的狗完成签到,获得积分10
31秒前
kais完成签到 ,获得积分10
35秒前
liyuqi61148完成签到,获得积分10
36秒前
搞怪的小粉完成签到,获得积分10
37秒前
渤123发布了新的文献求助20
39秒前
Amber完成签到,获得积分10
41秒前
魯蛋完成签到,获得积分10
41秒前
42秒前
49秒前
50秒前
图样图森破完成签到,获得积分10
50秒前
NexusExplorer应助姜建正采纳,获得10
51秒前
嗯哼发布了新的文献求助10
53秒前
高分求助中
Sustainability in Tides Chemistry 2800
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Handbook of Qualitative Cross-Cultural Research Methods 600
Very-high-order BVD Schemes Using β-variable THINC Method 568
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3137664
求助须知:如何正确求助?哪些是违规求助? 2788576
关于积分的说明 7787679
捐赠科研通 2444950
什么是DOI,文献DOI怎么找? 1300139
科研通“疑难数据库(出版商)”最低求助积分说明 625814
版权声明 601023